Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;12(4):5088-5098.
doi: 10.1002/cam4.5253. Epub 2022 Oct 13.

Optimized decision support for selection of transoral robotic surgery or (chemo)radiation therapy based on posttreatment swallowing toxicity

Affiliations

Optimized decision support for selection of transoral robotic surgery or (chemo)radiation therapy based on posttreatment swallowing toxicity

Mehdi Hemmati et al. Cancer Med. 2023 Feb.

Abstract

Background: A primary goal in transoral robotic surgery (TORS) for oropharyngeal squamous cell cancer (OPSCC) survivors is to optimize swallowing function. However, the uncertainty in the outcomes of TORS including postoperative residual positive margin (PM) and extranodal extension (ENE), may necessitate adjuvant therapy, which may cause significant swallowing toxicity to survivors.

Methods: A secondary analysis was performed on a prospective registry data with low- to intermediate-risk human papillomavirus-related OPSCC possibly resectable by TORS. Decision trees were developed to model the uncertainties in TORS compared with definitive radiation therapy (RT) and chemoradiation therapy (CRT). Swallowing toxicities were measured by Dynamic Imaging Grade of Swallowing Toxicity (DIGEST), MD Anderson Dysphagia Inventory (MDADI), and the MD Anderson Symptom Inventory-Head and Neck (MDASI-HN) instruments. The likelihoods of PM/ENE were varied to determine the thresholds within which each therapy remains optimal.

Results: Compared with RT, TORS resulted in inferior swallowing function for moderate likelihoods of PM/ENE (>60% in short term for all instruments, >75% in long term for DIGEST and MDASI) leaving RT as the optimal treatment. Compared with CRT, TORS remained the optimal therapy based on MDADI and MDASI but showed inferior swallowing outcomes based on DIGEST for moderate-to-high likelihoods of PM/ENE (>75% for short-term and >40% for long-term outcomes).

Conclusion: In the absence of reliable estimation of postoperative PM/ENE concurrent with significant postoperative PM, the overall toxicity level in OPSCC patients undergoing TORS with adjuvant therapy may become more severe compared with patients receiving nonsurgical treatments thus advocating definitive (C)RT protocols.

Keywords: decision analysis; definitive (chemo)radiation therapy; head-and-neck cancer; oropharyngeal squamous cell cancer; posttreatment toxicity; transoral robotic surgery.

PubMed Disclaimer

Conflict of interest statement

Dr. Fuller received/receives funding and salary support from directly related to this project from: NIH National Institute of Dental and Craniofacial Research (NIDCR) Academic Industrial Partnership Grant (R01DE028290); NIDCR Establishing Outcome Measures for Clinical Studies of Oral and Craniofacial Diseases and Conditions award (R01DE025248); NIH/NSF NCI Smart Connected Health Program (R01CA257814). Dr. Fuller received/receives funding and salary support from directly unrelated to this project from: NCI Parent Research Project Grant (R01CA258827); NCI Ruth L. Kirschstein NRSA Institutional Research Training Grant (T32CA261856); NIH NIDCR Exploratory/Developmental Research Grant Program (R21DE031082); National Institutes of Health (NIH) National Cancer Institute (NCI) Early Stage Development of Technologies in Biomedical Computing, Informatics, and Big Data Science Program (R01CA214825); NSF/NIH Joint Initiative on Quantitative Approaches to Biomedical Big Data program (R01CA225190); NIH National Institute of Biomedical Imaging and Bioengineering (NIBIB) Research Education Programs for Residents and Clinical Fellows Grant (R25EB025787); NCI Early Phase Clinical Trials in Imaging and Image‐Guided Interventions Program (1R01CA218148); NIH/NCI Cancer Center Support Grant (CCSG) Pilot Research Program Award from the UT MD Anderson CCSG Radiation Oncology and Cancer Imaging Program (P30CA016672); Small Business Innovation Research Grant Program a sub‐award from Oncospace, Inc. (R43CA254559); The Human BioMolecular Atlas Program (HuBMAP) Integration, Visualization & Engagement (HIVE) Initiative (OT2OD026675) sub‐award; Patient‐Centered Outcomes Research Institute (PCS‐1609‐36,195) sub‐award from Princess Margaret Hospital; National Science Foundation (NSF) Division of Civil, Mechanical, and Manufacturing Innovation (CMMI) grant (NSF 1933369). Dr. Fuller receives grant and infrastructure support from MD Anderson Cancer Center via the Charles and Daneen Stiefel Center for Head and Neck Cancer Oropharyngeal Cancer Research Program; the Program in Image‐guided Cancer Therapy; and the NIH/NCI Cancer Center Support Grant (CCSG) Radiation Oncology and Cancer Imaging Program (P30CA016672). Dr. Fuller has received direct industry grant/in‐kind support, honoraria, and travel funding from Elekta AB. TCS was supported by The University of Texas Health Science Center at Houston Center for Clinical and Translational Sciences TL1 Program (TL1 TR003169).

Figures

FIGURE 1
FIGURE 1
(Top) The underlying process for determining the eligibility of the patient for TORS and its probabilistic outcomes; (Bottom) General decision Tree for TORS decision‐making; scenario 1: definitive RT versus TORS; scenario 2: CRT versus TORS; pM+pM: probability of having (not having) positive margins after surgery; pN+pN: probability of having (not having) extranodal extension after surgery; pTM+pTM: probability of having tumor resection margin of more (less) than 2 mm after surgery; CRT, chemoradiation therapy; RT, radiation therapy; TORS, transoral robotic surgery
FIGURE 2
FIGURE 2
Expected deterioration in swallowing function for the first scenario based on (A) short‐term measures and (B) long‐term measures. cS, cut‐off value for TORS; DDIGEST, DIGEST‐based absolute short‐term deterioration in swallowing function; RDIGEST, DIGEST‐based absolute long‐term deterioration in swallowing function; ΔLMDADI, MDADI‐based absolute long‐term deterioration; ΔLMDASI, MDASI‐based absolute long‐term deterioration; ΔSMDADI, MDADI‐based absolute short‐term deterioration; ΔSMDASI, MDASI‐based absolute short‐term deterioration; r, risk associated with TORS; RT, radiation therapy; TORS, transoral robotic surgery
FIGURE 3
FIGURE 3
Expected deterioration in swallowing function for the second scenario based on (A) short‐term measures and (B) long‐term measures. cS, cut‐off value for TORS; DDIGEST, DIGEST‐based absolute short‐term deterioration in swallowing function; RDIGEST, DIGEST‐based absolute long‐term deterioration in swallowing function; ΔLMDADI, MDADI‐based absolute long‐term deterioration; ΔLMDASI, MDASI‐based absolute long‐term deterioration; ΔSMDADI, MDADI‐based absolute short‐term deterioration; ΔSMDASI, MDASI‐based absolute short‐term deterioration; CRT, chemoradiation therapy; r, risk associated with TORS; TORS, transoral robotic surgery

References

    1. Baskin RM, Boyce BJ, Amdur R, et al. Transoral robotic surgery for oropharyngeal cancer: patient selection and special considerations. Cancer Manag Res. 2018;10:839‐846. - PMC - PubMed
    1. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29(32):4294‐4301. - PMC - PubMed
    1. National Cancer Institute – Head and Neck Cancers . Accessed September 10, 2021. https://www.cancer.gov/types/head‐and‐neck/head‐neck‐fact‐sheet
    1. Centers for Disease Control and Prevention – Head and Neck Cancers . Accessed September 29, 2021. https://www.cdc.gov/cancer/headneck/
    1. Jamal Z, Anjum F. Oropharyngeal Squamous Cell Carcinoma. StatPearls; 2020. - PubMed

Publication types

MeSH terms